Reflux and Dyspepsia

When acid blockers stop working (and what's actually going on).

May 20, 2026 · Rick Pescatore, DO

The acid blocker stopped working. That is almost never the actual problem.

The story plays out the same way in clinic after clinic. Someone with burning, pressure, or that hot feeling behind the breastbone starts a proton-pump inhibitor (PPI), a class of drugs that shuts down stomach acid production. They feel better for a few months. Then the burn comes back. They double the dose. It gets worse. They walk into the office convinced their body has learned to ignore the medication.

It usually has not. True pharmacologic tolerance to PPIs is uncommon. What people call tolerance is almost always a different diagnosis surfacing through symptoms that were never fully about acid in the first place.

What the early relief actually meant

PPIs are precise drugs. They block the final step in gastric acid secretion. When acid is genuinely the driver, they work, and they work fast. So when someone with overlapping upper-gut symptoms starts a PPI and feels better, two things can be happening at once. The acid component quiets down. And whatever else is going on, the gut wiring, the motility, the mucosal sensitivity, simply has not flared yet.

A few months in, the second piece catches up. The PPI keeps doing its job on acid. The burn keeps coming back anyway. That is the signal.

The leading suspects when a PPI stops working

When upper-gut symptoms outrun acid suppression, four diagnoses sit at the top of the list. They overlap with each other and with gastroesophageal reflux disease (GERD, the disease where stomach acid actually damages the esophagus), which is why most people get a generic reflux label and stop there.

Functional dyspepsia (FD) is the most common one and the most missed. FD is a disorder of gut-brain interaction (DGBI), meaning the structural exam looks normal but the wiring between the gut and the brain is misfiring. The classic FD pattern includes epigastric burning, fullness after small meals, and early satiety. Rome V, the international diagnostic framework for DGBI, treats FD as the upper-stomach mirror of irritable bowel syndrome (IBS). It overlaps with GERD symptoms so heavily that the two are routinely confused at the bedside.

Eosinophilic esophagitis (EoE) is an allergic, immune-driven inflammation of the esophagus. It often presents as reflux that does not respond to acid blockers, food sticking, or a vague chest discomfort. It is increasingly common and underdiagnosed because the only way to find it is biopsies during endoscopy.

Gastroparesis is delayed stomach emptying. Food sits in the stomach too long. The pressure pushes back up. It feels like reflux. It is not.

Bile reflux is the backflow of bile from the small intestine into the stomach and sometimes the esophagus. PPIs do not touch bile. If bile is the irritant, more acid suppression cannot help.

What Rome V says about FD

Rome V keeps FD in two main subtypes: epigastric pain syndrome (burning and pain in the upper abdomen) and postprandial distress syndrome (fullness and early satiety after meals). Most patients have features of both. The diagnostic threshold is symptoms at least three days a month, present for the last three months, with onset at least six months ago. Crucially, the criteria explicitly note that FD symptoms can overlap with GERD and often do not improve with acid suppression alone.

When to push for a real workup

Doubling the PPI is not a workup. It is a delay. If symptoms have come back despite an adequate trial of acid suppression, the question is no longer how much more acid blocker to add. The question is what else is going on.

An upper endoscopy with biopsies is the single highest-yield test in this situation. Done right, it splits the field. Biopsies of the esophagus can rule in or out EoE by counting eosinophils, the immune cells that drive the disease. Biopsies of the stomach can identify Helicobacter pylori, a treatable bacterial infection that causes a meaningful share of dyspepsia. Some centers now also count mast cells in the duodenum, which is emerging as a marker in FD.

Specific things worth asking your physician to evaluate during the workup: esophageal eosinophil count, gastric H. pylori testing, mast-cell density in the duodenal biopsy if available, and a gastric emptying study if early fullness and nausea are dominant.

What actually moves functional dyspepsia

Once FD is the working diagnosis, the treatment list looks nothing like the GERD playbook. Acid suppression is not the lever. The wiring is. Five categories of intervention have the strongest signal in the FD literature.

Low-dose prokinetics. These are drugs that nudge the stomach to empty faster. They are not heartburn medications. They target the motility piece of FD directly. Several agents have evidence in this space, with the specific choice depending on country and availability.

Low-dose neuromodulators. Tricyclic antidepressants like nortriptyline, given at doses well below those used for depression, dampen the gut-brain hypersensitivity loop. Talley et al, in a multicenter trial published in 2015, showed that low-dose amitriptyline meaningfully improved symptoms in the epigastric-pain subtype of FD. The neuromodulator does not treat low mood. It quiets the visceral signaling.

Mucosal protectants. Mastic gum and zinc-carnosine have small but real evidence bases for upper-gut symptoms. Mastic gum is a tree resin used in Mediterranean medicine for centuries; modern trials suggest it can reduce dyspepsia symptom scores. Zinc-carnosine, originally developed in Japan, has shown benefit in protecting and repairing gastric mucosa in NSAID-induced injury and reflux-like symptoms.

Motility cofactors. Ginger is the best-studied: Hu et al, in a 2011 crossover trial, showed that ginger accelerated gastric emptying compared with placebo. Thiamine, vitamin B1, sits underneath autonomic function and gut motility; deficiency, even subclinical, tracks with delayed emptying and bloating in patients with DGBI.

Gut-directed hypnotherapy. This is not a soft option. It is the most evidence-backed mind-body intervention for upper-gut DGBI. Calvert et al published one of the early controlled trials in FD in 2002, showing sustained benefit at long-term follow-up. Most major DGBI guidelines now list it as a first-line option, not a fallback.

The pattern under the burn

Functional dyspepsia rarely travels alone. It clusters with IBS, migraine, fibromyalgia, anxiety, and sleep disruption. The shared substrate is central sensitization, the nervous system dialing up signal across multiple channels. If the burn is part of a larger pattern, the treatment plan should be, too.

What to do

Stop escalating the PPI before reassessing. Doubling the dose when the burn returns is the most common wrong turn, and it delays the real diagnosis by months.
Ask your physician about an upper endoscopy with biopsies, specifically for eosinophil count (EoE), H. pylori, and mast-cell density if available. This is the single highest-yield step when PPI-treated symptoms relapse.
If gastroparesis is suspected, ask about a gastric emptying study. If bile reflux is suspected, ask about evaluation for that specifically, since acid suppression will not address it.
While the workup is underway, trial mucosal and motility-supportive interventions: mastic gum, zinc-carnosine, ginger, and adequate B1 status. These are low-risk and address mechanisms PPIs cannot reach.
Loop your physician in on neuromodulators and gut-directed hypnotherapy if symptoms persist. Low-dose nortriptyline and structured hypnotherapy are both first-line tools in functional dyspepsia, not last resorts.

When the acid blocker stops working, the answer is rarely more acid blocker. The answer is a better diagnosis.